ECM
EFTRW

Evolution Capital Management’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Evolution Capital Management’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$8.19K Hold
50,000
– – 0.03% 43
2022
Q3 		$10K Hold
50,000
– – 0.01% 53
2022
Q2 		$13K Buy
+50,000
New +$13.6K 0.02% 49

Other funds holding EFTRW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ICM
III Capital Management Boca Raton, Florida $344M AUM 11.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Evolution Capital Management's EFTRW Position: Q4 2022 in Review

Evolution Capital Management held its eFFECTOR Therapeutics, Inc. Warrant (EFTRW) position steady in Q4 2022 at 50,000 shares worth $8.19K. The position accounts for 0.03% of the portfolio, ranked #43.

Evolution Capital Management first reported a position in EFTRW in Q2 2022 and has held it in 3 quarters since. The position peaked at $13K in Q2 2022. 12 funds tracked by Wall St. Rank hold EFTRW as of Q4 2022.

  • Evolution Capital Management held 50,000 shares of eFFECTOR Therapeutics, Inc. Warrant worth $8.19K as of Q4 2022.
  • Evolution Capital Management left its eFFECTOR Therapeutics, Inc. Warrant share count unchanged in Q4 2022.
  • eFFECTOR Therapeutics, Inc. Warrant made up 0.03% of Evolution Capital Management's portfolio in Q4 2022, its #43 holding.
  • Evolution Capital Management first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q2 2022 and has held it in 3 quarters since.
  • Evolution Capital Management's eFFECTOR Therapeutics, Inc. Warrant position peaked at $13K in Q2 2022.
  • 12 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q4 2022.

Based on Evolution Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.